771
Participants
Start Date
February 29, 2012
Primary Completion Date
April 30, 2014
Study Completion Date
April 30, 2014
TMC435
TMC435 Type=exact number, unit=mg, number=150, form=capsule, route=oral use. TVR placebo Form=tablet, route=oral use. TMC435 capsule is taken once daily in addition to 2 TVR placebo tablets 3 times a day for 12 weeks, and peginterferon alfa-2a and ribavirin for 48 weeks.
TVR
TVR Type=exact number, unit=mg, number=375, form=tablet, route=oral use. TMC435 placebo Form=capsule, route=oral use. 2 TVR tablets are taken 3 times a day together with 150 mg TMC435 placebo capsule once daily for 12 weeks, in addition to peginterferon alfa-2a and ribavirin for 48 weeks
Bakersfield
San Diego
Aurora
Washington D.C.
Jacksonville
Orlando
West Palm Beach
Atlanta
Honolulu
Chicago
Crestview Hills
New Orleans
Chevy Chase
Jackson
Tupelo
Kansas City
Missoula
Newark
New York
Rochester
Cincinnati
Cleveland
Allentown
Philadelphia
Pittsburgh
Arlington
Houston
Odessa
San Antonio
Falls Church
Bellevue
Seattle
Buenos Aires
Rosario, Santa Fe
Darlinghurst
Greenslopes
Kingswood
Melbourne
Parkville - Vic
Perth
Sydney
Woolloongabba
Linz
Vienna
Brussels
Haine-Saint-Paul, La Louviere
Leuven
Liège
Campinas
Ribeirão Preto
Salvador
São Paulo
Sofia
Varna
Calgary
Edmonton
Vancouver
Toronto
Montreal
Brno
Karlovy Vary
Pilsen
Prague
Copenhagen
Hvidovre
Odense
Grenoble
Lyon
Marseille
Nice
Paris
Pessac
Vandœuvre-lès-Nancy
Berlin
Frankfurt
Freiburg im Breisgau
Hamburg
Hanover
Heidelberg
Kiel
Mainz
München
Stuttgart
Ulm
Würzburg
Alexandroupoli
Athens
Larissa
Budapest
Debrecen
Kaposvár
Pécs
Szeged
Haifa
Jerusalem
Petah Tikva
Ramat Gan
Safed
Tel Aviv
Fredrikstad
Nordbyhagen
Stavanger
Tromsø
Bydgoszcz
Chorzów
Kielce
Lodz
Lublin
Mysłowice
Racibórz
Warsaw
Lisbon
Porto
Santurce
Bucharest
Constanța
Iași
Timișoara
Barcelona
Madrid
Santander
Seville
Valencia
Gothenburg
Lund
Malmo
Örebro
Stockholm
Lugano
Sankt Gallen
Zurich
Glasgow
Leeds
London
Newcastle upon Tyne
Plymouth
Southampton
Janssen R&D Ireland
INDUSTRY